Last €151.46 EUR
Change Today -5.34 / -3.41%
Volume 181.0
ILU On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 3:14 PM 12/23/14 All times are local (Market data is delayed by at least 15 minutes).

illumina inc (ILU) Snapshot

Open
€153.40
Previous Close
€156.80
Day High
€154.77
Day Low
€150.00
52 Week High
10/31/14 - €159.00
52 Week Low
01/6/14 - €78.58
Market Cap
21.5B
Average Volume 10 Days
164.9
EPS TTM
--
Shares Outstanding
142.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ILLUMINA INC (ILU)

illumina inc (ILU) Details

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. The company’s products include sequencing platforms that are based on its SBS technology are designed to meet the various demands of a range of sequencing applications; and array platforms consist of HiScan and iScan systems that are array scanners, which support the imaging of array-based genetic analysis products. It also offers various sample preparation and sequencing kits to simplify workflows and accelerate analysis. In addition, the company provides genotyping and whole genome sequencing services. It serves genomic research centers, academic institutions, government laboratories, hospitals, and reference laboratories, as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic, and consumer genomics companies. The company sells its products directly, as well as through distributors. It has strategic partnerships with AstraZeneca PLC; Janssen Biotech, Inc.; and Sanofi to focus on the transition from single-analyte companion diagnostics to panel-based assays that select for companion therapeutics. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.

3,000 Employees
Last Reported Date: 02/18/14
Founded in 1998

illumina inc (ILU) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $1.1M
President and Director
Total Annual Compensation: $153.5K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $447.7K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $457.1K
Senior Vice President of Corporate Developmen...
Total Annual Compensation: $449.6K
Compensation as of Fiscal Year 2013.

illumina inc (ILU) Key Developments

HudsonAlpha Institute for Biotechnology Announces Purchase of HiSeq X Ten Sequencing System Manufactured by Illumina, Inc

HudsonAlpha Institute for Biotechnology announced it has purchased the HiSeq X Ten sequencing system manufactured by Illumina Inc. The technology will enable HudsonAlpha to produce and analyze genomic data faster and at a lower cost. The purchase stems from the Institute's commitment to research programs for genomics excellence in patient care. The HiSeq X Ten provides unprecedented capacity, speed and accuracy for sequencing individuals' entire genetic make-up or DNA their whole genome. HudsonAlpha will integrate the HiSeq X Ten into its current high-volume production environment at its Genomic Services Laboratory. The technology will make it possible for HudsonAlpha to produce and analyze genomic data on timescales and at a cost that are relevant to enable routine human whole genome sequencing.

bioMérieux and Illumina Enter Agreement to Co-Develop a Next-Generation Sequencing Solution for Epidemiological Monitoring of Bacterial Infections

bioMérieux and Illumina announced that they have signed an exclusive agreement to launch a next-generation sequencing (NGS) epidemiology solution for service labs. The two companies will jointly develop applications for microbiology sequencing technologies within a four-year renewable period. The first application will be an NGS epidemiological solution offered by service labs for genotyping disease agents. The high resolution of NGS combined with bioMerieux's knowledge in microbiology will provide easily accessible and highly accurate information to communities and hospitals to track, prevent, contain and stop the spread of disease agents. The solution will combine Illumina's MiSeq(R) sequencing system with a jointly developed pathogen genome database based on bioMérieux's culture collection. This collection, which contains over 80,000 references, constitutes libraries of bacterial strains in the world, and will contribute to creating a database of unprecedented scope with information about virulence and microbial resistance characteristics. The service will deliver a standardized report with a genomic profile of the infectious agents, with sequence-level accuracy and depth of information. The ultimate goal of the Illumina-bioMérieux epidemiology solution will be to enable public health and hospital microbiology laboratories to contain an epidemic, avoid transmission of infectious agents, and improve hospital practices where needed. Those facing a suspected epidemic or health crisis will be able to send the relevant isolates to a designated laboratory equipped with an Illumina sequencing system. The genetic sequences will be sent via a secure cloud platform to be analyzed, using the database and software developed by bioMérieux, which will also generate a customized report for the customer. The precise results will be presented seamlessly, in an easily understandable graphical format identifying the infectious agent as well as the sequence-based genetic variations that would assist in understanding its transmission.

HTG Announces Completion of IVD Development and Supply Agreement With Illumina

HTG Molecular Diagnostics Inc. announced that it entered into an agreement with Illumina Inc., under which HTG will have the right to develop certain in-vitro diagnostic (IVD) test kits that utilize Illumina sequencing technology.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ILU:GR €151.46 EUR -5.34

ILU Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Avago Technologies Ltd $100.62 USD -0.10
Becton Dickinson and Co $139.34 USD -0.56
Dr Reddy's Laboratories Ltd 3,134 INR -0.3498
Sigma-Aldrich Corp $137.21 USD +0.05
Waters Corp $114.35 USD -0.19
View Industry Companies
 

Industry Analysis

ILU

Industry Average

Valuation ILU Industry Range
Price/Earnings 99.1x
Price/Sales 15.3x
Price/Book 21.0x
Price/Cash Flow 83.9x
TEV/Sales 13.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ILLUMINA INC, please visit www.illumina.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.